CBLL

Ceribell, Inc. (CBLL) - Q1 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Quarterly Report on Form 10-Q for Ceribell, Inc. for the period ended March 31, 2026. Ceribell is a commercial-stage medical technology company developing the Ceribell System, a point-of-care electroencephalography (EEG) platform utilizing AI-powered algorithms for the diagnosis and monitoring of seizures and delirium in acute care settings. As of the reporting date, the system is deployed in over 650 hospitals in the United States.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 29% year-over-year, driven by a 29% increase in both product revenue (sales of disposable Wearables) and subscription revenue (Clarity portal and recorder fees). Growth was attributed to new customer acquisitions and increased utilization within existing accounts.
• Operating Expenses: Total operating expenses rose 36% to $43.9 million.
  • General and Administrative (G&A): Increased 54% to $15.3 million, primarily due to a $4.8 million increase in professional services related to intellectual property enforcement (patent litigation against Natus Medical).
  • Sales and Marketing: Increased 24% to $22.4 million due to headcount expansion.
  • Research and Development: Increased 45% to $6.2 million, driven by personnel costs.
• Liquidity: Cash and cash equivalents increased to $45.3 million, while marketable securities decreased to $95.9 million. The company reported a net cash increase of $4.8 million for the quarter, primarily due to maturities of marketable securities offsetting operating cash outflows.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($141.2 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring losses as it scales commercial operations and R&D.
• Legal Proceedings: The company is engaged in patent infringement litigation against Natus Medical Incorporated, filed in July 2025 with the USITC and District Court. As of March 31, 2026, the company has a commitment to pay $2.9 million in deferred legal fees contingent on settlement or a favorable initial determination. No provision has been recorded for these fees.
• Tariff Uncertainty: Following a February 2026 Supreme Court ruling invalidating certain tariffs, the company estimates it paid approximately $1.6 million under the affected statute. The potential for a refund remains uncertain, and no asset has been recognized.
• Regulatory Milestones: In December 2025, the FDA granted 510(k) clearance for Ceribell's delirium monitoring solution. In January 2026, the company received Breakthrough Device Designation for its Ceribell LVO System (stroke detection).
• Non-GAAP Measures: Adjusted EBITDA for Q1 2026 was $(11.2) million, compared to $(10.9) million in Q1 2025. Adjustments included stock-based compensation ($3.7 million) and IP litigation costs ($5.6 million).

Investor Verification Checklist

• Legal Fee Contingency: Verify the status of the $2.9 million deferred legal fee commitment related to the Natus litigation and the likelihood of payment.
• Tariff Refund Status: Monitor updates regarding the potential recovery of the $1.6 million in tariffs paid under the invalidated IEEPA statute.
• Customer Utilization Rates: Assess whether revenue growth is driven by new hospital acquisitions or increased usage (Wearables) per existing hospital, as this impacts recurring revenue stability.
• Debt Covenants: Review the terms of the $20 million term loan (maturing 2029) to ensure compliance with covenants, particularly given the company's continued net losses.
• Supply Chain Resilience: Evaluate risks associated with reliance on contract manufacturers in China and Vietnam for key components, considering geopolitical tensions and trade policy changes.